• Customer Care
  • (888) 123-4567

News

At Rise Therapeutics, we are advancing oral precision immunotherapy, developing first-in-class immune modulatory drugs. Our breakthrough therapies target inflammation, autoimmunity, and cancer, offering innovative, patient-friendly solutions to transform treatment paradigms. Stay tuned for the latest updates on our clinical progress, partnerships, and scientific advancements as we push the boundaries of oral immune therapy.

Rise Therapeutics Secures New Funding to Advance First-in-Class R-2487 Oral Immune Biomodulator into Sjogren’s Disease Clinical Testing

Rockville, MD — September 23, 2025— Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, today announced it will be initiating clinical evaluation of R-2487 in SjD.

Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3-6

Rockville, MD., April 7, 2025 -- Rise Therapeutics, a biopharmaceutical company developing precision immunotherapies, today announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference in San Diego on May 6th.

Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer

Rockville, Maryland, January 13, 2025 – Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.

Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials

Rockville, Maryland, January 6th, 2025 – Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.

New Funding Secured to Support Clinical GMP Manufacturing Expansion Expansion at Rise Therapeutics

Rockville, Maryland, October 22nd, 2024- Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health (NIH) to enable infrastructure improvement that will scale GMP production and accelerate quality assurance (QA) and quality control (QC), significantly enhancing its biologics drug manufacturing capabilities. This Commercial Readiness Pilot (CRP) Program SBIR award will also support Phase 2 clinical GMP manufacturing to advance Rise Therapeutics’ R-3750 program currently completing a Phase 1 proof-of-concept clinical trial in patients suffering from ulcerative colitis.

First Type 1 Diabetes Patient Enrolled in Rise Therapeutics’ Latest Clinical Trial

Rockville, Maryland, July 15th, 2024 – Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has enrolled its first patient in its R-5280 placebo controlled, blinded, Phase 1b type 1 diabetes clinical trial.